Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcium pretreatment for diltiazem-related hypotension in AFib
NCT06494007Phase 4
Key facts
- Status
- Completed
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Countries
- 1
- Sponsor
- Haseki Training and Research Hospital
- Modality
- Small Molecules
- Drugs
- calcium chloride
- Conditions
- hypotension
01
Overview
Phase 4, randomised, triple-blind trial of calcium chloride in hypotension, sponsored by Haseki Training and Research Hospital. Started Jan 2023; status: completed.
02
Design
- Study design
- RandomizedTriple-blind
03
Who it enrols
Adults with AFib/AFL, HR >= 120 bpm, and SBP >= 90 mmHg, excluding those with hemodynamic instability, specific heart blocks, or recent use of other rate control agents.
04
Registry description
The objective of this study is to examine the efficacy and safety of IV calcium pretreatment at varying doses prior to weight-adjusted IV Diltiazem on the incidence of Diltiazem-related hypotension in adult patients presenting to the Emergency Department due to Atrial Fibrillation with Rapid Ventricular Response. Specifically, we tested the hypothesis that patients with Atrial Fibrillation who receive IV calcium pretreatment prior to IV Diltiazem suffer less hypotension than those receiving Diltiazem monotherapy.
Beyond the preview
Go deeper on NCT06494007.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494007.